Inventor
MALCOLM MACCOSS
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds31%
A61KPreparations for medical, dental or toiletry purposes19%
Y02ATechnologies for adaptation to climate change13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
PatentTitleYear
12,528,816Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors202611,912,721Fused pentacyclic imidazole derivatives202411,795,172Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors202311,479,546Antimalarial hexahydropyrimidine analogues202211,136,310Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2024Patents assigned to UCB Biopharma SRL (3)· patent assignee history
2021Patents assigned to UCB BIOPHARMA SPRL (1)· patent assignee history
2021–2026Based in US· patent location history
2022Based in SC· patent location history
2023–2026Patents assigned to CARDURION PHARMACEUTICALS INC (2)· patent assignee history
2024Patents assigned to SANOFI SA (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UCB Biopharma SRL | 3 | 2021–2024 |
| CARDURION PHARMACEUTICALS INC | 2 | 2023–2026 |
| SANOFI SA | 1 | 2024 |
| UCB BIOPHARMA SPRL | 1 | 2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 4 | 2021–2026 |
| SC | 1 | 2022 |